. "Jedn\u00E1 se o aplikovan\u00FD v\u00FDzkum v oblasti farmakogenetiky a farmakokinetiky. Bude zji\u0161\u0165ov\u00E1no, zda \u00FAsp\u011B\u0161nost a bezpe\u010Dnost l\u00E9\u010Dby prvn\u00EDch epizod schizofrenie risperidonem souvis\u00ED s fenotypem a genotypem 2D6 izoformy cytochromu P450 (CYP2D6). Do projektu bude za\u0159azeno 25-30 pacient\u016F (dle mo\u017Enost\u00ED) s prvn\u00ED epizodou schizofrenie, kte\u0159\u00ED budou l\u00E9\u010Deni risperidonem. Fenotyp CYP2D6 bude zji\u0161\u0165ov\u00E1n na po\u010D\u00E1tku, v pr\u016Fb\u011Bhu a na konci terapie a genotyp 1x p\u0159i za\u0159azen\u00ED do studie. V pr\u016Fb\u011Bhu a ke konci terapie budou sledov\u00E1ny parametry \u00FAsp\u011B\u0161nosti a bezpe\u010Dnosti (nap\u0159. v\u00FDskyt ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F) terapie. Tyto parametry budou n\u00E1sledn\u011B statisticky vyhodnoceny s ohledem na p\u0159\u00EDslu\u0161nost ke genotypu / fenotypu pacient\u016F a budou vytipov\u00E1ni pacienti s rizikem v\u00FDskytu ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F a pacienti - nonrespond\u00E9\u0159i." . . . " effectiveness" . " phenotype" . . . . "NS9676" . "http://www.isvav.cz/projectDetail.do?rowId=NS9676"^^ . . "The project is focused on the research in the field of clinical pharmacokinetics and pharmacogenetics. The project is going to clarify the relationship between the phenotype/genotype and effectiveness and occurence of adverse effects of the risperidone therapy in the first episodes of schizophrenia. In the project, 25 (up to 30) patients with the first attack of schizophrenia treated with risperidone will be included in the study. Phenotype of CYP2D6 will be assessed at the beginning of the study, in the course, and finally at the end of hospitalization; genotype will be determined once during the hospitalization. Parameters of the effectiveness and safety will be assessed continuously during the hospitalization. Consecutively, these parameters will be statistically evaluated with respect to the assessed genotype/phenotype of CYP2D6. Patients with higher risk of adverse effects and patients-nonresponders will be found out."@en . . "2011-08-08+02:00"^^ . . "The influence of pharmacogenetic and pharmacokinetic factors on the efficacy and safety of the first schizophrenia episodes therapy"@en . " CYP2D6" . "U celkem p\u011Bti pomal\u00FDch metaboliz\u00E1tor\u016F s prvn\u00ED epizodou schizoftrenie byl pozorov\u00E1n ni\u017E\u0161\u00ED terapeutick\u00FD efekt risperidonu v porovn\u00E1n\u00ED s pacienty s obvyklou aktivitou CYP2D6. Tato data ze souboru 35 pacient\u016F je v\u0161ak nutn\u00E9 ov\u011B\u0159it v \u0159\u00E1dn\u00E9 klinick\u00E9 studii."@cs . . . . . "genotype; phenotype; cytochrome; CYP2D6; schizophrenia; risperidone; effectiveness; safety"@en . "9"^^ . "2013-10-31+01:00"^^ . . "9"^^ . " risperidone" . . . " schizophrenia" . "1"^^ . "Totally 5 CYP2D6 poor metabolizers had worse treatment outcome in first epizode of schisophrenia. This data must, however, be confirmed in a correctly designed and conducted trials, since the total study population was only 35 subjects in the project."@en . "Vliv farmakogenetick\u00FDch a farmakokinetick\u00FDch faktor\u016F na \u00FA\u010Dinnost a bezpe\u010Dnost terapie prvn\u00EDch epizod schizofrenie" . "1"^^ . "2009-01-01+01:00"^^ . " cytochrome" . . "genotype" . . "0"^^ . . "2011-12-31+01:00"^^ .